BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15240604)

  • 1. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.
    Serhal DI; Nasrallah MP; Arafah BM
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3285-9. PubMed ID: 15240604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
    Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.
    Robbins RJ; Driedger A; Magner J;
    Thyroid; 2006 Nov; 16(11):1121-30. PubMed ID: 17123339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation for radioactive iodine administration in differentiated thyroid cancer patients.
    Liel Y
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):523-7. PubMed ID: 12354135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
    Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.
    Edmonds CJ; Hayes S; Kermode JC; Thompson BD
    Br J Radiol; 1977 Nov; 50(599):799-807. PubMed ID: 588901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
    Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
    Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of post-thyroidectomy treatment alternatives for triiodothyronine or thyroxine replacement in pediatric thyroid cancer patients.
    Ben-Shachar R; Eisenberg M; Huang SA; DiStefano JJ
    Thyroid; 2012 Jun; 22(6):595-603. PubMed ID: 22578300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical Effects of Levothyroxine Withdrawal in Patients with Differentiated Thyroid Cancer.
    Papadakis G; Kalaitzidou S; Triantafillou E; Drosou A; Kakava K; Dogkas N; Pappa T; Kaltzidou V; Tertipi A; Villiotou V; Pappas A
    Anticancer Res; 2015 Dec; 35(12):6933-40. PubMed ID: 26637919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning.
    Chow SM; Au KH; Choy TS; Lee SH; Yeung NY; Leung A; Leung A; Leung HL; Shek CC; Law SC
    Laryngoscope; 2006 Nov; 116(11):2060-6. PubMed ID: 17075410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy.
    Ito M; Miyauchi A; Morita S; Kudo T; Nishihara E; Kihara M; Takamura Y; Ito Y; Kobayashi K; Miya A; Kubota S; Amino N
    Eur J Endocrinol; 2012 Sep; 167(3):373-8. PubMed ID: 22711760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation.
    Grigsby PW; Siegel BA; Bekker S; Clutter WE; Moley JF
    J Nucl Med; 2004 Apr; 45(4):567-70. PubMed ID: 15073251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
    Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
    Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
    Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.